Stay updated on Perjeta & Herceptin in HER2+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Perjeta & Herceptin in HER2+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Perjeta & Herceptin in HER2+ Breast Cancer Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The page footer now displays Revision: v3.4.2 instead of Revision: v3.4.1.
    Difference
    0.0%
    Check dated 2026-02-13T17:39:44.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Revision updated from v3.4.0 to v3.4.1 in the site footer. No study data, eligibility criteria, outcomes, or navigation were changed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-06T11:44:12.000Z thumbnail image
  4. Check
    19 days ago
    Change Detected
    Summary
    Revision updated from v3.4.0 to v3.4.1 in the site footer. The previous revision label v3.4.0 has been removed.
    Difference
    0.0%
    Check dated 2026-02-05T14:28:25.000Z thumbnail image
  5. Check
    27 days ago
    Change Detected
    Summary
    Added a glossary toggle and updated QC metadata label to 'Last Update Submitted that Met QC Criteria' with a revision bump to v3.4.0. The old 'Last Update Submitted that met QC Criteria' label capitalization was replaced and the 'No FEAR Act data' label was replaced with 'No FEAR Act Data'.
    Difference
    0.1%
    Check dated 2026-01-29T04:31:30.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    Revision: v3.3.4 is now displayed on the page, replacing the previous Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T02:53:23.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    The page’s Locations section has been expanded to include a large list of study sites across the United States, Canada, and several European countries. The HHS Vulnerability Disclosure notice has been removed.
    Difference
    2%
    Check dated 2025-12-23T17:27:09.000Z thumbnail image

Stay in the know with updates to Perjeta & Herceptin in HER2+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Perjeta & Herceptin in HER2+ Breast Cancer Clinical Trial page.